Observational Study in patients with ExPEC disease following TRUS-PNB

  • Research type

    Research Study

  • Full title

    Prospective Evaluation of the Incidence of Extraintestinal Pathogenic Escherichia coli (ExPEC) Disease, O-seratype Prevalence of ExPEC, ExPEC Case Definition, and Health Outcomes Following Transrectal Ultrasound Guided Prostate Needle Biopsy (TRUS-PNB).

  • IRAS ID

    217015

  • Contact name

    James Green

  • Contact email

    james.green@bartshealth.nhs.uk

  • Sponsor organisation

    Janssen Research & Development

  • Duration of Study in the UK

    0 years, 10 months, 31 days

  • Research summary

    Janssen is currently developing ExPEC4V (JNJ-63771860), a 4-valent polysaccharide vaccine candidate for the prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. This observational study is intended to estimate the incidence of invasive ExPEC disease in patients undergoing TRUS-PNB in order to support the design of the Phase 3 clinical development program by describing the incidence of invasive ExPEC disease in men aged ≥18 years undergoing transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB) in treatment locations representative of the geographic areas in which the Phase 3 clinical trial will be conducted. Additionally, this study will assess the O-serotype distribution or prevalence of infecting E. coli isolates for patients experiencing invasive ExPEC disease following TRUS-PNB to determine O-serotype coverage for the vaccine. This study will also provide data to meet a regulatory request by the Centre for Biologics Evaluation and Research (CBER) to evaluate the Phase 3 clinical case definition for invasive ExPEC disease. Finally, this study will document the health outcomes and costs associated with invasive ExPEC disease and compare these outcomes to a similar population based on clinical characteristics without invasive ExPEC disease. No study drug will be administered in this non-interventional study.

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    17/LO/0069

  • Date of REC Opinion

    9 Jan 2017

  • REC opinion

    Favourable Opinion